# US 2019/0169305 A1 · Recombinant obligate anaerobic gram-positive bacteria

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0169305 A1
- Document ID: US20190169305A1
- Status: Published application
- Kind: A1
- Application number: 16/279,627
- Filed: 2019-02-19
- Published: 2019-06-06
- Earliest claimed: 2014-01-10
- Assignees: Teikyo Heisei University
- Applicants: Teikyo Heisei University
- Inventors: Takeshi Nishikawa; Yuichiro Taira; Ikuko Taira; Isao Ishida
- Web page: https://patentgrep.com/patent/US20190169305A1

## CPC

- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 15/746: {for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

An object of the present invention is to effectively induce cancer cell apoptosis using the anti-TRAIL-R1 antibody(ies) and the anti-TRAIL-R2 antibody(ies) and to reduce the toxicity imposed on normal cells. The present invention relates to recombinant obligate anaerobic Gram-positive bacteria that include a nucleic acid encoding a fusion protein having 3 or more anti-TRAIL-R1 single-chain antibodies and/or 3 or more anti-TRAIL-R2 single-chain antibodies, in an expressible state.

## Claims

### Claim 1

A method of treating a tumor, comprising administering recombinant bacteria of the genus Bifidobacterium to a subject in need thereof by an intravenous route;
wherein the recombinant bacteria comprise a nucleic acid encoding a fusion protein, the fusion protein comprising a signal peptide and 3 or more anti-TRAIL-R1 single-chain antibodies and/or 3 or more anti-TRAIL-R2 single-chain antibodies, in an expressible state.

### Claim 2 (depends on 1)

The method of claim 1, wherein each of the 3 or more anti-TRAIL-R1 single-chain antibodies comprises CDR1, CDR2 and CDR3, wherein the CDR1 comprises the amino acid sequence of SEQ ID NO: 22, the CDR2 comprises the amino acid sequence of SEQ ID NO: 23; and the CDR3 comprises the amino acid sequence of SEQ ID NO: 24.

### Claim 3 (depends on 1)

The method of claim 1, wherein each of the 3 or more anti-TRAIL-R2 single-chain antibodies comprises CDR1, CDR2 and CDR3, wherein the CDR1 comprises the amino acid sequence of SEQ ID NO: 15, the CDR2 comprises the amino acid sequence of SEQ ID NO: 16, and the CDR3 comprises the amino acid sequence of SEQ ID NO: 17.

### Claim 4 (depends on 1)

The method of claim 1, wherein the fusion protein further comprises one or more functional peptides.

### Claim 5 (depends on 4)

The method of claim 4, wherein the functional peptides comprise a labeling protein.

### Claim 6 (depends on 1)

The method of claim 1, wherein the tumor is a colon cancer or a pancreatic cancer.

### Claim 7 (depends on 1)

The method of claim 1, where the recombinant Bifidobacterium expresses and secretes a 4E6 tetramer.

### Claim 8 (depends on 1)

The method of claim 1, wherein the subject is a mammal.
